BrainStorm Files Patent Application for Stem Cell Procedure with Potential for Multiple Sclerosis Therapy
BrainStorm Cell Therapeutics (OTCBB:BCLI), the developer of NurOwn(TM) bone marrow derived stem cell therapeutic products for the treatment of neurodegenerative diseases, announced today that a patent application has been filed with the US Patent and Trademark Office for a new procedure to derive oligodendrocyte-like cells.
Article
Cytori Therapeutics Receives CE Mark for the Celutionâ„¢ Stem Cell System; Achieves Condition for $11.0 Million Milestone Payment from Olympus Collaboration
This approval is the first CE Mark given for a device that can process adult stem cells from adipose (fat) tissue.
Article
Geron Announces Improved Production Method for Human Embryonic Stem Cell-Derived Islet Cells
Geron Corporation (Nasdaq:GERN) announced today the presentation of a new production protocol to differentiate islet cells from human embryonic stem cells (hESCs) for the treatment of diabetes.
Article
Amgen and Genentech Sign License Agreements For Antibody Patents
Amgen (NASDAQ:AMGN) and Genentech Inc. (NYSE:DNA) today announced that they have entered into license agreements granting licenses to each other under multiple patents relating to the manufacture and use of antibodies and related technology.
Article
Amgen to Make Significant Investment in Manufacturing, R&D and Commercial Operations Expansion
Amgen (Nasdaq: AMGN), the world’s largest biotechnology company, today announced that it anticipates significant investment in additional manufacturing and R&D operations in the United States and Europe and expansion of its commercial operations into new markets.
Article
Becton Dickinson Studies Stem Cell Market
U.S. medical products company Becton Dickinson and Co. (BDX.N: Quote, Profile, Research) has started to explore the commercial potential of stem cells as a treatment for diabetes, its chief executive said on Wednesday.
Article
ReNeuron Receives Notice of Allowance from US Patent Office for Neural Stem Cell Transplantation Patent Application
ReNeuron Group plc (LSE: RENE.L) today announced that it has received a Notice of Allowance from the US Patent and Trademark Office concerning a key patent application for methods of transplantation of neural stem cells.
Article
Medistem Reports Novel Method of Immunomodulation Through Genetic Reprogramming of Immune Cells Medistem Laboratories, Inc. (OTCBB:MDSM), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, announced today the successful development of a novel method of immune response modification utilizing a genetic reprogramming technology involving RNA interference.
Article
Weizmann Institute Scientists Suggest that Immune Cells Help to Maintain Cognition and Brain Cell Renewal
A team of scientists at the Weizmann Institute of Science, led by Prof. Michal Schwartz of the Neurobiology Department, has come up with new findings that may have implications in delaying and slowing down deterioration of memory and learning ability in old age.
Article
Targeted Genetics Corporation (TGEN) Strengthens Intellectual Property For AAV Vector Manufacturing Purification Processes
Targeted Genetics Corporation (Nasdaq:TGEN) today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector manufacturing processes. U.S. patent #6,989,264 is titled, “Methods for generating high titer helper-free preparation of released recombinant AAV vectors.”
Article
Shareholders of Inex Pharmaceuticals Approve Spin Out of Targeted Immunotherapy Assets
Inex Pharmaceuticals Corporation (“INEX”;TSX: IEX) announced that at its Special Meeting of Shareholders held today, shareholders of INEX approved the Plan of Arrangement to complete the spin-out of INEX’s Targeted Immunotherapy assets into a new company, Tekmira Pharmaceuticals Corporation (“Tekmira”) with 98.3% of shares cast voting in favour of the spin-out.
Article
FDA Blasts Boston Scientific Over cGMP Violations
The FDA is putting Boston Scientific on notice that the company’s quality management practices are insufficient, with “serious regulatory problems” being found at numerous facilities.
Article
MicroIslet Appoints Dr. James R. Gavin III Interim President and CEO
MicroIslet, Inc. (Amex: MII) today announced that it has appointed James R. Gavin III, M.D., Ph.D., as its interim President and CEO, effective January 20, 2006. Dr. Gavin has been a member of MicroIslet’s Board of Directors since March 2001.
Article